ArticleDiscover oncology2026
Peripheral blood IFN-γ-producing T-cell subsets and soluble IL-2 receptor as independent prognostic biomarkers in NSCLC treated with immune checkpoint inhibitor-based therapy.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundImmune checkpoint inhibitor(ICI)-based therapy has revolutionized non-small-cell lung cancer (NSCLC) treatment, yet reliable biomarkers for monitoring immune response in real time remain elusive. MATERIALS AND
methodsIn NSCLC patients, lymphocyte counts and function through interferon (IFN)-γ secretion in CD4
resultsThe study found that different therapies induced distinct patterns of immune remodeling. ICI-based therapy significantly increased IFN-γ secretion by CD4 + and CD8 + T cells (both P < 0.05) and decreased sIL-2R levels (P < 0.01). Radiotherapy activated T cell function but caused marked lymphocytopenia (P < 0.001). Chemotherapy did not produce significant immune fluctuations. Multivariate analysis confirmed that high IFN-γ + CD4 + T cell levels (HR = 0.19, P = 0.014) and high sIL-2R levels (HR = 29.03, P < 0.001) were independent prognostic factors for progression-free survival (PFS). The nomogram integrating these indicators demonstrated excellent predictive performance (C-index = 0.867).
conclusionThis study demonstrated the value of peripheral blood immune-function indicators for monitoring treatment response and showed that a composite model based on IFN-γ CD4
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.